請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38945
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江俊斌 | |
dc.contributor.author | Huang-Hsu Chen | en |
dc.contributor.author | 陳皇旭 | zh_TW |
dc.date.accessioned | 2021-06-13T16:53:47Z | - |
dc.date.available | 2006-07-05 | |
dc.date.copyright | 2005-07-05 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-06-16 | |
dc.identifier.citation | Adams Martin A. Dionne I. Wellinger RJ. Holm C. The function of DNA polymerase alpha at telomeric G tails is important for telomere homeostasis. Molecular & Cellular Biology. 20(3):786-96, 2000 Feb.
Aikata H. Takaishi H. Kawakami Y. Takahashi S. Kitamoto M. Nakanishi T. Nakamura Y. Shimamoto F. Kajiyama G. Ide T. Telomere reduction in human liver tissues with age and chronic inflammation. Experimental Cell Research. 256(2):578-82, 2000 May 1. Aisner DL. Wright WE. Shay JW. Telomerase regulation: not just flipping the switch. Current Opinion in Genetics & Development. 12(1):80-5, 2002 Feb. Alfonso-De Matte MY. Cheng JQ. Kruk PA. Ultraviolet irradiation- and dimethyl sulfoxide-induced telomerase activity in ovarian epithelial cell lines. Experimental Cell Research. 267(1):13-27, 2001 Jul 1. Asai A. Kiyozuka Y. Yoshida R. Fujii T. Hioki K. Tsubura A. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Research. 18(3A):1465-72, 1998 May-Jun. Biessmann H. Mason JM. Telomerase-independent mechanisms of telomere elongation. Cellular & Molecular Life Sciences. 60(11):2325-33, 2003 Nov. Blackburn EH. Switching and signaling at the telomere. Cell. 106(6):661-73, 2001 Sep 21. Blasco MA. Immunosenescence phenotypes in the telomerase knockout mouse. Springer Seminars in Immunopathology. 24(1):75-85, 2002. Blasco MA. Mammalian telomeres and telomerase: why they matter for cancer and aging. European Journal of Cell Biology. 82(9):441-6, 2003a Sep. Blasco MA. Telomeres and cancer: a tale with many endings. Current Opinion in Genetics & Development. 13(1):70-6, 2003b Feb. Blasco MA. Hahn WC. Evolving views of telomerase and cancer. Trends in Cell Biology. 13(6):289-94, 2003 Jun. Califano J. Ahrendt SA. Meininger G. Westra WH. Koch WM. Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Research. 56(24):5720-2, 1996 Dec 15. Chen HM. Yen-Ping Kuo M. Lin KH. Lin CY. Chiang CP. Expression of cyclin A is related to progression of oral squamous cell carcinoma in Taiwan. Oral Oncology. 39(5):476-82, 2003 Jul. Chen JL. Blasco MA. Greider CW. Secondary structure of vertebrate telomerase RNA. Cell. 100(5):503-14, 2000 Mar 3. Chen YK. Huang HC. Lin LM. Lin CC. Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncology. 35(2):173-9, 1999 Mar. Chiang CP. Huang JS. Wang JT. Liu BY. Kuo YS. Hahn LJ. Kuo MY. Expression of p53 protein correlates with decreased survival in patients with areca quid chewing and smoking-associated oral squamous cell carcinomas in Taiwan. Journal of Oral Pathology & Medicine. 28(2):72-6, 1999 Feb. Cong YS. Wright WE. Shay JW. Human telomerase and its regulation. Microbiology & Molecular Biology Reviews. 66(3):407-25, table of contents, 2002 Sep. Curran AJ. Gullane PJ. Irish J. Macmillan C. Freeman J. Kamel-Reid S. Telomerase activity is upregulated in laryngeal squamous cell carcinoma. Laryngoscope. 110(3 Pt 1):391-6, 2000 Mar. Curran AJ. St Denis K. Irish J. Gullane PJ. MacMillan C. Kamel-Reid S. Telomerase activity in oral squamous cell carcinoma. Archives of Otolaryngology -- Head & Neck Surgery. 124(7):784-8, 1998 Jul. de Lange T. Protection of mammalian telomeres. Oncogene. 21(4):532-40, 2002 Jan 21.Nagpal JK. Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncology. 39(3):213-21, 2003 Apr. DePinho RA. The age of cancer. Nature. 408(6809):248-54, 2000 Nov 9. Ducrest AL. Szutorisz H. Lingner J. Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene. 21(4):541-52, 2002 Jan 21. Effros RB. Telomeres and HIV disease. Microbes & Infection. 2(1):69-76, 2000 Jan. Eversole LR. Sapp JP. c-myc oncoprotein expression in oral precancerous and early cancerous lesions. European Journal of Cancer. Part B, Oral Oncology. 29B(2):131-5, 1993 Apr. Fabricius EM. Gurr U. Wildner GP. Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head-and-neck. Analytical Cellular Pathology. 24(1):25-39, 2002. Feng J. Funk WD. Wang SS. Weinrich SL. Avilion AA. Chiu CP. Adams RR. Chang E. Allsopp RC. Yu J. et al. The RNA component of human telomerase. Science. 269(5228):1236-41, 1995 Sep 1. Finnon P. Silver AR. Bouffler SD. Upregulation of telomerase activity by X-irradiation in mouse leukaemia cells is independent of Tert, Terc, Tnks and Myc transcription. Carcinogenesis. 21(4):573-8, 2000 Apr. Frost M. Bobak JB. Gianani R. Kim N. Weinrich S. Spalding DC. Cass LG. Thompson LC. Enomoto T. Uribe-Lopez D. Shroyer KR. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. American Journal of Clinical Pathology. 114(5):726-34, 2000 Nov. Fujimoto R. Kamata N. Taki M. Yokoyama K. Tomonari M. Nagayama M. Yasumoto S. Gene expression of telomerase related proteins in human normal oral and ectocervical epithelial cells. Oral Oncology. 39(5):445-52, 2003 Jul. Fujimoto R. Kamata N. Yokoyama K. Ueda N. Satomura K. Hayashi E. Nagayama M. Expression of telomerase components in oral keratinocytes and squamous cell carcinomas. Oral Oncology. 37(2):132-40, 2001 Feb. Goytisolo FA. Blasco MA. Many ways to telomere dysfunction: in vivo studies using mouse models. Oncogene. 21(4):584-91, 2002 Jan 21. Griffith JD. Comeau L. Rosenfield S. Stansel RM. Bianchi A. Moss H. de Lange T. Mammalian telomeres end in a large duplex loop. Cell. 97(4):503-14, 1999 May 14. Hackett JA. Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 21(4):619-26, 2002 Jan 21. Harley CB. Telomerase is not an oncogene. Oncogene. 21(4):494-502, 2002 Jan 21. Helder MN. Wisman GB. van der Zee GJ. Telomerase and telomeres: from basic biology to cancer treatment. Cancer Investigation. 20(1):82-101, 2002. Hiyama E. Hiyama K. Clinical utility of telomerase in cancer. Oncogene. 21(4):643-9, 2002 Jan 21. Horikawa I. Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis. 24(7):1167-76, 2003 Jul. Jeng JH. Kuo ML. Hahn LJ. Kuo MY. Genotoxic and non-genotoxic effects of betel quid ingredients on oral mucosal fibroblasts in vitro. Journal of Dental Research. 73(5):1043-9, 1994 May. Karlseder J. Smogorzewska A. de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 295(5564):2446-9, 2002 Mar 29. Karlseder J. Telomere repeat binding factors: keeping the ends in check. Cancer Letters. 194(2):189-97, 2003 May 15. Kim HR. Christensen R. Park NH. Sapp P. Kang MK. Park NH. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clinical Cancer Research. 7(10):3079-86, 2001 Oct. Kim MY. Vankayalapati H. Shin-Ya K. Wierzba K. Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. Journal of the American Chemical Society. 124(10):2098-9, 2002 Mar 13. Kim Sh SH. Kaminker P. Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene. 21(4):503-11, 2002 Jan 21. Klapper W. Qian W. Schulte C. Parwaresch R. DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia. 17(10):2007-15, 2003 Oct. Komata T. Kanzawa T. Kondo Y. Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene. 21(4):656-63, 2002 Jan 21. Koscielny S. Eggeling F. v. Dahse R. Fiedler W. The influence of reactivation of the telomerase in tumour tissue on the prognosis of squamous cell carcinomas in the head and neck. Journal of Oral Pathology & Medicine. 33(9):538-42. Koyanagi K. Ozawa S. Ando N. Kitagawa Y. Ueda M. Kitajima M. Clinical significance of telomerase activity in peripheral blood of patients with esophageal squamous cell carcinoma. Annals of Thoracic Surgery. 73(3):927-32, 2002 Mar. Krupp G. Klapper W. Parwaresch R. Cell proliferation, carcinogenesis and diverse mechanisms of telomerase regulation. Cellular & Molecular Life Sciences. 57(3):464-86, 2000 Mar. Kumaki F. Kawai T. Hiroi S. Shinomiya N. Ozeki Y. Ferrans VJ. Torikata C. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Human Pathology. 32(2):188-95, 2001 Feb. Kumamoto H. Kinouchi Y. Ooya K. Telomerase activity and telomerase reverse transciptase (TERT) expression in ameloblastomas. Journal of Oral Pathology & Medicine. 30(4):231-6, 2001 Apr. Kuo MYP. Huang JS. Kok SH. Kuo YS. Chiang CP. Prognostic role of p21WAF1 expression in areca quid chewing and smoking-associated oral squamous cell carcinoma in Taiwan. Journal of Oral Pathology & Medicine. 31(1):16-22, 2002 Jan. Kuo MYP. Lin CY. Hahn LJ. Cheng SJ. Chiang CP. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. Journal of Oral Pathology & Medicine. 28(4):165-9, 1999 Apr. Kyo S. Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy?. Oncogene. 21(4):688-97, 2002 Jan 21. Lantuejoul S. Soria JC. Moro-Sibilot D. Morat L. Veyrenc S. Lorimier P. Brichon PY. Sabatier L. Brambilla C. Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. British Journal of Cancer. 90(6):1222-9, 2004 Mar 22. Mao L. El-Naggar AK. Fan YH. Lee JS. Lippman SM. Kayser S. Lotan R. Hong WK. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Research. 56(24):5600-4, 1996 Dec 15. Meeker AK. De Marzo AM. Recent advances in telomere biology: implications for human cancer. Current Opinion in Oncology. 16(1):32-8, 2004 Jan. Mergny JL. Riou JF. Mailliet P. Teulade-Fichou MP. Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Research. 30(4):839-65, 2002 Feb 15. Mese H. Ueyama Y. Suzuki A. Nakayama S. Sasaki A. Hamakawa H. Matsumura T. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy. 47(2):136-42, 2001 Mar-Apr. Mitsui A. Kuwabara Y. Iwase H. Mitani M. Shinoda N. Sato A. Toyama T. Sugiura M. Suzuki T. Kato J. Fujii Y. Telomerase activity in esophageal squamous cell carcinoma: down-regulation by chemotherapeutic agent. Journal of Surgical Oncology. 79(1):37-45, 2002 Jan. Mutirangura A. Supiyaphun P. Trirekapan S. Sriuranpong V. Sakuntabhai A. Yenrudi S. Voravud N. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Research. 56(15):3530-3, 1996 Aug 1. Nagpal JK. Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncology. 39(3):213-21, 2003 Apr. Nakatani K. Yoshimi N. Mori H. Yoshimura S. Sakai H. Shinoda J. Sakai N. The significant role of telomerase activity in human brain tumors. Cancer. 80(3):471-6, 1997 Aug 1. Newbold RF. The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis. 17(6):539-50, 2002 Nov. Parkinson EK. Newbold RF. Keith WN. The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation. European Journal of Cancer. 33(5):727-34, 1997 Apr. Poole JC. Andrews LG. Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 269(1-2):1-12, 2001 May 16. Poremba C. Scheel C. Hero B. Christiansen H. Schaefer KL. Nakayama J. Berthold F. Juergens H. Boecker W. Dockhorn-Dworniczak B. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. Journal of Clinical Oncology. 18(13):2582-92, 2000 Jul. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 21(3):477-84, 2000 Mar Sakai H. Kawano K. Okamura K. Hashimoto N. Immunohistochemical localization of c-myc oncogene product and EGF receptor in oral squamous cell carcinoma. Journal of Oral Pathology & Medicine. 19(1):1-4, 1990 Jan. Seimiya H. Sawada H. Muramatsu Y. Shimizu M. Ohko K. Yamane K. Tsuruo T. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO Journal. 19(11):2652-61, 2000 Jun 1. Sharpless NE. DePinho RA. Telomeres, stem cells, senescence, and cancer. Journal of Clinical Investigation. 113(2):160-8, 2004 Jan. Shay JW. At the end of the millennium, a view of the end. Nature Genetics. 23(4):382-3, 1999 Dec. Shroyer KR. Thompson LC. Enomoto T. Eskens JL. Shroyer AL. McGregor JA. Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix. American Journal of Clinical Pathology. 109(2):153-62, 1998 Feb. Snijders PJ. van Duin M. Walboomers JM. Steenbergen RD. Risse EK. Helmerhorst TJ. Verheijen RH. Meijer CJ. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Research. 58(17):3812-8, 1998 Sep 1. Son NH. Murray S. Yanovski J. Hodes RJ. Weng N. Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age. Journal of Immunology. 165(3):1191-6, 2000 Aug 1. Sundqvist K. Liu Y. Nair J. Bartsch H. Arvidson K. Grafstrom RC. Cytotoxic and genotoxic effects of areca nut-related compounds in cultured human buccal epithelial cells. Cancer Research. 49(19):5294-8, 1989 Oct 1. Tahara H. Yasui W. Tahara E. Fujimoto J. Ito K. Tamai K. Nakayama J. Ishikawa F. Tahara E. Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene. 18(8):1561-7, 1999 Feb 25. te Poele RH. Okorokov AL. Jardine L. Cummings J. Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Research. 62(6):1876-83, 2002 Mar 15. Tumuluri V. Thomas GA. Fraser IS. The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma. Journal of Oral Pathology & Medicine. 33(4):204-8, 2004 Apr. Ulaner GA. Hu JF. Vu TH. Giudice LC. Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Research. 58(18):4168-72, 1998 Sep 15. Urquidi V. Tarin D. Goodison S. Role of telomerase in cell senescence and oncogenesis. Annual Review of Medicine. 51:65-79, 2000. Wada H. Enomoto T. Yoshino K. Ozaki K. Kurachi H. Nomura T. Murata Y. Kim N. Weinrich S. Lea-Chou E. Lopez-Uribe D. Shroyer KR. Immunohistochemical localization of telomerase hTERT protein and analysis of clonality in multifocal vulvar intraepithelial neoplasia. American Journal of Clinical Pathology. 114(3):371-9, 2000 Sep. Wei R. Younes M. Immunohistochemical detection of telomerase reverse transcriptase in colorectal adenocarcinoma and benign colonic mucosa. Human Pathology. 33(7):693-6, 2002 Jul. Wenz C. Enenkel B. Amacker M. Kelleher C. Damm K. Lingner J. Human telomerase contains two cooperating telomerase RNA molecules. EMBO Journal. 20(13):3526-34, 2001 Jul 2. Wong JM. Collins K. Telomere maintenance and disease. Lancet. 362(9388):983-8, 2003 Sep 20. Wynn RF. Cross MA. Hatton C. Will AM. Lashford LS. Dexter TM. Testa NG. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 351(9097):178-81, 1998 Jan 17. Yajima Y. Noma H. Furuya Y. Nomura T. Yamauchi T. Kasahara K. Hatada K. Takano M. Quantification of telomerase activity of regions unstained with iodine solution that surround oral squamous cell carcinoma. Oral Oncology. 40(3):314-20, 2004 Mar. Yasui W. Tahara E. Tahara H. Fujimoto J. Naka K. Nakayama J. Ishikawa F. Ide T. Tahara E. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Japanese Journal of Cancer Research. 90(6):589-95, 1999 Jun. Yoo J. Park SY. Kang SJ. Kim BK. Shim SI. Kang CS. Expression of telomerase activity, human telomerase RNA, and telomerase reverse transcriptase in gastric adenocarcinomas. Modern Pathology. 16(7):700-7, 2003 Jul. Yu HP. Xu SQ. Lu WH. Li YY. Li F. Wang XL. Su YH. Telomerase activity and expression of telomerase genes in squamous dysplasia and squamous cell carcinoma of the esophagus. Journal of Surgical Oncology. 86(2):99-104, 2004 May 1. Zhou XZ. Perrem K. Lu KP. Role of Pin2/TRF1 in telomere maintenance and cell cycle control. Journal of Cellular Biochemistry. 89(1):19-37, 2003 May 1. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38945 | - |
dc.description.abstract | 背景: 端粒酶活性和人類端粒酶反轉錄酶訊息核醣核甘酸(hTERT mRNA)的過度表現,已經在不同的人類癌症中被發現,且和腫瘤的大小,淋巴結的轉移,腫瘤分期,復發和預後等有關。
方法: 在本研究中,我們利用免疫組織化學染色法,探討hTERT蛋白質在82例口腔鱗狀細胞癌(OSCC),116例口腔上皮變異(OED),21例正常口腔黏膜(NOM)之表現。計算hTERT在OSCC、OED、和NOM細胞質和細胞核內的染色強度(SI),染色指標(LIs,定義為在所有細胞中陽性染色細胞的百分比)和染色記分(LSs,定義為染色強度與染色指標的乘積)並比較組間差異。利用統計分析OSCCs細胞質或細胞核LSs和臨床參數或存活率間的關連性。 結果: 結果顯示平均細胞質hTERT LSs從NOM (87±17%), 經OED (95±18%) 至OSCC 樣本 (114±33%, P=0.000),呈統計上有意義增加。平均細胞核hTERT LSs從NOM (80±14%)至OED (91±20%)也是增加,但至OSCC樣本(86±35%)則下降,三組間並無明顯統計上差異。平均細胞質hTERT LSs和OSCCs發生在男性(P=0.023),較大的腫瘤體積 (T3和T4,P=0.048),較高的臨床分期(第3和4期,P=0.033),或患者有嚼食檳榔(P=0.029),抽菸(P=0.027)和喝酒(P=0.025)等習慣有明顯相關。進一步看,OSCC患者若細胞核hTERT LSs高於100%,則復發率較高(P=0.044),和五年存活率較低(P=0.011)。 結論: 我們的結果支持hTERT的過度表現在口腔癌形成早期即已發生,hTERT可作為OSCCs的生物指標。量測OSCC樣本細胞質或細胞核內hTERT的表現,也許可預測口腔癌的進程、復發和預後。 | zh_TW |
dc.description.abstract | Background: Overexpression of telomerase activity or human telomerase reverse transcriptase (hTERT) mRNA has been demonstrated in a variety of human cancers and found to be associated with the tumor size, lymph node metastasis, clinical stage, recurrence, or prognosis of these cancers.
Methods: In this study, we examined the expression of hTERT protein in 82 specimens of oral squamous cell carcinoma (OSCC), 116 specimens of oral epithelial dysplasia (OED), and 21 specimens of normal oral mucosa (NOM) by immunohistochemistry. The cytoplasmic and nuclear hTERT staining intensity (SI), labeling indices (LIs, defined as the percentage of positive cells in total cells), and labeling scores (LSs, defined as SI × LI) in OSCC, OED, and NOM samples were calculated and compared between groups. The correlation between the cytoplasmic or nuclear hTERT LS in OSCCs and clinicopathological parameters or survival of OSCC patients was analyzed statistically. Results: The mean cytoplasmic hTERT LSs increased significantly from NOM (87±17%) through OED (95±18%) to OSCC samples (114±33%, P=0.000). The mean nuclear hTERT LSs also increased from NOM (80±14%) to OED (91±20%) and then decreased to OSCC samples (86±35%) with no statistically significant difference among the 3 groups. A significant correlation was found between the higher mean cytoplasmic hTERT LSs and OSCCs occurring in male patients (P=0.023), with larger tumor sizes (T3 and T4, P=0.048), with more advanced clinical stages (stages 3 and 4, P=0.033), or from patients with areca quid chewing (P=0.029), cigarette smoking (P=0.027), or alcohol drinking habits (P=0.025). In addition, OSCC patients with nuclear hTERT LSs greater than 100% were prone to have cancer recurrence (P=0.044) and a lower 5-year survival rate (P=0.011). Conclusion: Our results suggest that the increased expression of hTERT is an early event in oral carcinogenesis and hTERT may be a biomarker for OSCCs. Measuring the amount of cytoplasmic or nuclear expression of hTERT in OSCC samples may predict the oral cancer progression, recurrence, and prognosis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T16:53:47Z (GMT). No. of bitstreams: 1 ntu-94-R92422005-1.pdf: 750561 bytes, checksum: a70f4dd4e6c040bf6a61467033c14ed0 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 中文摘要…………………………………………………………………… 7
Abstract ……………………………………………………………………8 Introduction …………………………………………………………… 10 Background ………………………………………………………………13 Purposes of this study………………………………………………… 15 Literature Review Telomere………………………………………………………………… 16 Structure ………………………………………………………………… 16 Associated proteins……………………………………………………… 18 Senescence……………………………………………………………………20 Associated conditions ……………………………………………………24 ALT……………………………………………………………………… 24 Telomerase…………………………………………………………………25 hTERT…………………………………………………………………28 Structure……………………………………………………………28 Regulation……………………………………………………………29 hTR………………………………………………………………………38 Associated proteins………………………………………………………40 Tumor………………………………………………………………………42 Associated studies………………………………………………………… 46 Head and neck SCCs …………………………………………………46 Other tumors………………………………………………………… 49 Therapy……………………………………………………………………54 Associated drugs………………………………………………………… 55 Materials and methods Part 1: Patients and specimens……………………………………………………... 57 Part 2: Immunohistochemical staining for hTERT …………………….………….. 58 Part 3: Statistical analysis…………………………………………………….…….. 60 Results Part 1: Expression of hTERT and mean LIs and LSs for OSCC, OED, and NOM samples ………………………………………………….…61 Part 2: Correlation between the mean hTERT LI or LS in OSCCs and clinicopathological parameters of OSCC patients ………………… 62 Part 3: Correlation between the mean hTERT LI or LS in OSCCs and oral habits of OSCC patients …………………………………………………63 Part 4: Correlation between cytoplasmic or nuclear hTERT LS in OSCCs and recurrence or survival of OSCC patients …………………… 63 Discussion……………………………………………………………65 Conclusion……………………………………………………………71 References…………………………………………………………… 72 Tables………………………………………………………………… 82 Figures…………………………………………………………………88 Tables Table 1. The mean hTERT labeling indices (LI) and labeling scores (LS) in normal oral mucosa (NOM), oral epithelial dysplasia (OED), and oral squamous cell carcinoma (OSCC) samples……………..……………..………………………….. 82 Table 2 Correlation between cytoplasmic or nuclear hTERT labeling indices (LI) in OSCC samples and clinicopathological parameters of OSCC patients ..…….... 83 Table3 Correlation between cytoplasmic or nuclear hTERT labeling scores (LS) in OSCC samples and clinicopathological parameters of OSCC patients ………… 84 Table 4 Correlation between cytoplasmic or nuclear hTERT labeling indices (LI) in OSCC samples and oral habits (OH) of OSCC patients …………………… 85 Table 5 Correlation between cytoplasmic or nuclear hTERT labeling scores (LS) in OSCC samples and oral habits (OH) of OSCC patients .……………………… 86 Table 6 Correlation between cytoplasmic or nuclear hTERT labeling scores (LS) in OSCC samples and tumor recurrence ………………………………………… 87 Figures Figure 1. Immunohistochemical staining for hTERT……..………………………... 88 Figure 2 Kaplan–Meier survival curves of 62 patients with oral SCC followed completed or more than 5 years…………………………………………………….. 90 Figure 3 Kaplan–Meier survival curves of 82 patients with oral SCC. (T)………... 92 Figure 4 Kaplan–Meier survival curves of 82 patients with oral SCC. (N)………... 94 Figure 5 Kaplan–Meier survival curves of 82 patients with oral SCC. (Stage)……. 96 | |
dc.language.iso | en | |
dc.title | 人類端粒酶反轉錄酶於口腔鱗狀細胞癌與口腔癌前病變之表現 | zh_TW |
dc.title | Expression of human telomerase reverse transcriptase in oral squamous cell carcinomas and precancerous lesions | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張龍昌,關學婉 | |
dc.subject.keyword | 人類端粒酶,反轉錄酶,口腔癌,口腔癌前病變, | zh_TW |
dc.subject.keyword | human telomerase reverse transcriptase,oral cancer,oral precancer, | en |
dc.relation.page | 97 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-06-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 732.97 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。